sign in
join free
verified
Ordinary
Shanghai Rendu Biotechnology co., Ltd
verified
Shanghai Rendu Biotechnology co., Ltd
Shanghai,China
Shanghai Rendu Biotechnology co., Ltd
Shanghai,China
verified
Ordinary Member
Shanghai Rendu Biotechnology co., Ltd
favorite supplier
verified
Ordinary Member
Shanghai Rendu Biotechnology co., Ltd
Shanghai,China
Scan QR code
Access to mobile station
Shanghai Rendu Biotechnology co., Ltd
Founded in 2007, Rendu Biotechnology Co., Ltd is a public company committed to offer innovative RNA molecular testing solutions which not only have higher sensitivity, accuracy than other methodologies based on DNA testing, but also enable better assessment and monitoring of disease progression and treatment efficacy.
Based on our proprietary technology Simultaneous Amplification and Testing (SAT), we developed a fully automated sample-to-result molecular diagnostics testing platform AutoSAT, as well as a full range of assays for the detection of reproductive tract pathogen, respiratory tract pathogen, enterovirus and bloodborne infectious diseases.
All our products are developed under EN ISO 13485 and 23 of them have been designed, developed and validated in accordance with the Directive 98/79/EC on in vitro diagnostic medical devices (CE-IVD).
At present, we severs more than 500 medical institutions in China, 70% of them are Tier 3, Grade A hospitals. We are striving to expand global footprint and deliver the benefit of the speed and accuracy of molecular diagnostics to more patients, enabling a higher quality of care, lower costs, and improved outcomes.
+
More
Based on our proprietary technology Simultaneous Amplification and Testing (SAT), we developed a fully automated sample-to-result molecular diagnostics testing platform AutoSAT, as well as a full range of assays for the detection of reproductive tract pathogen, respiratory tract pathogen, enterovirus and bloodborne infectious diseases.
All our products are developed under EN ISO 13485 and 23 of them have been designed, developed and validated in accordance with the Directive 98/79/EC on in vitro diagnostic medical devices (CE-IVD).
At present, we severs more than 500 medical institutions in China, 70% of them are Tier 3, Grade A hospitals. We are striving to expand global footprint and deliver the benefit of the speed and accuracy of molecular diagnostics to more patients, enabling a higher quality of care, lower costs, and improved outcomes.
leave a message
-
phone :
view details
-
address :
Block A, Building 15, NO.528 Ruiqing Road, East District, Zhangjiang High Tech Park, Shanghai, P.R China
-
postcode :
201201
-
website :
www.rdbio.com